Abstract
MicroRNAs (miRNAs) are significant regulators of human hematopoietic stem cells (HSC), and their deregulation contributes to hematological malignancies. Myelodysplastic syndromes (MDS) represent a spectrum of hematological disorders characterized by dysfunctional HSC, ineffective blood cell production, progressive marrow failure, and an increased risk of developing acute myeloid leukemia (AML). Although miRNAs have been primarily studied in AML, only recently have similar studies been performed on MDS. In this review, we describe the normal function and expression of miRNAs in human HSC, and describe mounting evidence that deregulation of miRNAs contributes to the pathogenesis of MDS.
Keywords: microRNA, Myelodysplastic syndrome, microarray, hematopoietic stem cells (HSC), acute myeloid leukemia (AML), epigenetic modifying drugs, chemotherapy, refractory anemia (RA), ringed sideroblasts (RARS), 5q- syndrome
Current Pharmaceutical Design
Title:Implication of microRNAs in the Pathogenesis of MDS
Volume: 18 Issue: 22
Author(s): Jing Fang, Melinda Varney and Daniel T. Starczynowski
Affiliation:
Keywords: microRNA, Myelodysplastic syndrome, microarray, hematopoietic stem cells (HSC), acute myeloid leukemia (AML), epigenetic modifying drugs, chemotherapy, refractory anemia (RA), ringed sideroblasts (RARS), 5q- syndrome
Abstract: MicroRNAs (miRNAs) are significant regulators of human hematopoietic stem cells (HSC), and their deregulation contributes to hematological malignancies. Myelodysplastic syndromes (MDS) represent a spectrum of hematological disorders characterized by dysfunctional HSC, ineffective blood cell production, progressive marrow failure, and an increased risk of developing acute myeloid leukemia (AML). Although miRNAs have been primarily studied in AML, only recently have similar studies been performed on MDS. In this review, we describe the normal function and expression of miRNAs in human HSC, and describe mounting evidence that deregulation of miRNAs contributes to the pathogenesis of MDS.
Export Options
About this article
Cite this article as:
Fang Jing, Varney Melinda and T. Starczynowski Daniel, Implication of microRNAs in the Pathogenesis of MDS, Current Pharmaceutical Design 2012; 18 (22) . https://dx.doi.org/10.2174/1381612811209023170
DOI https://dx.doi.org/10.2174/1381612811209023170 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Resveratrol: A New Potential Therapeutic Agent for Melanoma?
Current Medicinal Chemistry Planar Cell Polarity Signaling in Collective Cell Movements During Morphogenesis and Disease
Current Genomics Role of Platelets in Angiogenesis in Health and Disease
Current Angiogenesis (Discontinued) Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia
Current Gene Therapy Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design IL-2 Receptor Targeted Immunomodulatory Biologics: The Past, Present, and Future
Current Immunology Reviews (Discontinued) Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments
Recent Patents on Anti-Cancer Drug Discovery Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design Rheumatologic Aspects of the COVID-19 Pandemic: A Practical Resource for Physicians in Kuwait and the Gulf region as Recommended by the Kuwait Association of Rheumatology
Current Rheumatology Reviews In vitro Generated Mesenchymal Stem Cells: Suitable Tools to Target Insulin Dependent Diabetes Mellitus?
Current Stem Cell Research & Therapy Imatinib and Its Successors – How Modern Chemistry has Changed Drug Development
Current Pharmaceutical Design Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Transcriptional Regulation of the p53 Tumor Suppressor Gene: A Potential Target for Cancer Therapeutics?
Recent Patents on DNA & Gene Sequences The Epidemiology of Sepsis
Current Pharmaceutical Design The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
Current Clinical Pharmacology Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes
Current Topics in Medicinal Chemistry Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Potential Use of Vanadium Compounds in Therapeutics
Current Medicinal Chemistry The Role of TRP Channels in Allergic Inflammation and its Clinical Relevance
Current Medicinal Chemistry